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Dear Editor
Office spirometry: temperature
conversion of volumes measured by
the Vitalograph-R bellows spirometer
is not necessary. (Respir Med 1999; 93:
685–688)This study compared one type of measuring instrumenta-
tion against another type of measuring instrumentation as a
reference device. The results obtained looked reasonable,
but the conclusions arrived at appeared to me to be
completely erroneous and without foundation.
I feel that it is important that your readers be aware that
there is now a widely accepted ‘reference device’ for
spirometers which most independent test laboratories have
adopted. We ourselves adopted this standard some years
ago, after extensive testing and comparison of our test data
with other test laboratories. This ‘reference device’ test
equipment is referred to as a Pulmonary Wave Form
Simulator (PWFS) and is specifically designed to have
performance characteristics capable of delivering the
defined test wave forms in the world definitive standard
for spirometry, the ATS 1994 standard.
Several test laboratories have published studies of this
test equipment and have been using this test equipment
since the 1994 adoption of the updated standard. Prior to
this, there were earlier versions of the standard which the
latest one has augmented.
This type of test equipment gives the definitive reference
device which can and is used at any location, to compare
the performance characteristics of pulmonary function
measurement devices.
My concern on the article above relates to the principle
of checking the accuracy of measured volumes using a
Volume Measurement Device with a flow measurement
device as the reference standard. To me, this is illogical and
poor use of technology.
If Dr Madsen and colleagues or any of your readers are
seriously interested in validating the accuracy of spiro-
meters, we are prepared to oer through your good oces,
an open invitation to view this very specialized test
equipment and procedures in our own test laboratories.
Further, to discuss with our technicians, the complexities
involved in the practical testing of spirometry devices and
the potential sources of error.
We are testing many spirometers every year and also
Peak Flow Meters against published reference standards.
This includes our own devices under development and
production and also most other devices on the market as
and when they are launched. We keep such reports0954-6111/00/090917+04 $35?00/0confidential, but would be happy to have any visitors
examine our data.
BERNARD R. GARBE
Managing Director,
For and on behalf of
Vitalograph Ltd,
Maids Moreton,
Buckingham, U.K.doi:10.1053/rmed.2000.0794
Dear Editor
Response to the letter from Mr Garbe
re: paper by Madsen et al. (Respir Med
1999; 93: 685–688)We have with great interest read the comments from
Bernard R. Garbe and we do find the considerations on
standards for calibration of spirometric equipment reason-
able and agree on almost all aspects.
The problem we addressed in our paper was very simple:
at what conditions are gas volumes inside the bellows of
Vitalograph-R spirometer during dynamic spirometry? The
answer, which should be equally simple, we have not found
published before.
Should we follow the ATS standards, as proposed by Mr
Garbe, ‘the spirometer temperature should be measured
and not assumed to be constant’ (1). We should therefore
be using volume spirometers with automated internal
temperature sensors only (2). In our opinion the Vitalo-
graph-R model has features that compensates for the lack
of internal temperature sensor, which still makes it an
attractive spirometer considering accuracy, precision, long
term durability and costs.
We are aware of the huge eorts that researchers and
manufactures of spirometric equipment put into calibration
of spirometers. We are also familier with the calibration
device, referred to by Mr Garbe, as the ‘definitive reference
device’ and originally described by Gardner (3).
It seems that Mr Garbe and we share in common a
genuine interest in calibration of spirometers and therefore
we suggest that Mr Garbe publish his results on volume
calibration of the Vitalograph-R model with and without
BTPS conversion of volumes. Only by doing so it will be
possible to judge the methods applied.
When it comes to the basics of any calibration, we need
‘an accepted reference value’ (4), the gold standard. In the
case of calibration of measuring instruments we rely on the
‘international standards’ (5) and therefore our calibrators
should be traceable to these standards. Even in the case of# 2000 HARCOURT PUBLISHERS LTD
918 LETTERS TO THE EDITORthe most well-esteemed equipment careful calibration of the
calibrators is mandatory (6). We did adopt the principles of
traceability to international standards throughout our
study and on the basis of this our results should be
weighted.
F. MADSEN
Department of Internal Medicine,
University of Copenhagen at
H. S. Frederiksberg Hospital,
Copenhagen, Denmark
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Dear Sir
Assessing lung deposition of inhaled
medications. Consensus statement
from a workshop of the British
Association for Lung Research, held at
the Institute of Biology, London, U.K.
on 17 April 1998. Snell NJC,
Ganderton D. eds. Respir Med 1999;
93: 123–133.cromoglycate were associated with dierences in regional
lung deposition and the decreased penetration seen with
more rapid inspiration was associated with reduced
protection against allergen challenge. The report then goes
on to state that this study correlates well with previous
work using a PK technique, showing that rapid inhalation
of sodium cromoglycate was associated with reduced total
lung deposition. The reference quoted is that of Richards
et al. (2). This in fact shows the complete opposite. The
study showed that the inspiratory flow rates measured of
184+ 14, 101+ 4, 57+ 3 lmin71 gave lung deposition, as
determined by AUC0–240, of 1245+ 220, 657+ 90 and
413+ 69 ngml71min respectively.
The dierences in these studied illustrate the dierences
in the techniques used in drug administration. Laube et al.
used a 1mg pressurized metered dose inhaler (MDI) with
the drug being placed into and inhaled from a 750ml
spacer. In these circumstances optimal lung deposition,
distribution and protection against allergen challenge is
given by slow inspiration. Richards et al. used a dry powder
inhaler, the Spinhaler, and the drug was inhaled from a
gelatine capsule. Using this method of administration,
rapid inspiration provides greater lung deposition and
greater protection. In the first case the particle size
characteristics of the inhaled drug is determined by the
dose size, the nozzle of the metered dose inhaler, and the
spacer. In the second case the particle sizes are largely
determined by the eciency with which the particular
device breaks up the large particles in the capsule into
smaller sizes. This in turn is largely determined by the speed
of inhalation through the device. Thus the two systems are
entirely dierent in the way in which they produce optimal
deposition within the lung. In the case of metered dose
pressurized inhalers, inhalation should be slow, around
30 lmin71. In the case of the Spinhaler, a dry powder
system, inhalation rates in excess of 120 lmin71 are
required.
An additional relevant study in this context is also by
Richards et al. (3,4) which measures the protective eect of
inhaled sodium cromoglycate against AMP-induced
bronchoconstriction using dierent inspiratory flow rates.
The drug was administered with the Spinhaler from gelatine
capsules. The inspiratory flow rates achieved were
221+ 87, 108+ 3 and 59+ 3 lmin71. The lung deposition
was 3318+ 925, 1702+ 378 and 1073+ 218 ngminml71.
The PC20AMP at each inspiratory rate were 136, 40 and 15.
Again, using a patient driven inhaler more rapid inhalation
gave greater lung deposition and greater protection against
challenge.
The report concludes that in vitro measurements of
aerosol fine particle fraction has a key role to play in the
development of new pharmaceutical products and in
quality control. A multistage apparatus should be used
over the particle size range 0?5–5?0mm. In Europe, apart
from Germany, the most widely used inhaled product of
sodium cromoglycate is the 5mgdose71 MDI. Applying
these criteria to the data provided in the paper by Newman
et al. (4), using the 5mg MDI, the lung deposition as
estimated by the fine particle fraction would be 15% of the
inhaled dose. That demonstrated by the radiolabelledIn the discussion section of this report, in which the
relationship between lung deposition of inhaled drugs and
clinical ecacy is discussed, there is an error in the
interpretation of one of the papers dealing with inhaled
sodium cromoglycate.
In the reference to the study by Laube et al. (1) it is stated
correctly that dierences in the rate of inhalation of sodium# 2000 HARCOURT PUBLISHERS LTD
